大多数转型项目在诊断阶段就失败，而诊断通常是从那些将因提供解决方案而获得报酬的人那里买来的。 B2B SaaS 公司面临特定困境——增长率从 42% 跌至 32%，而 60% 的收入集中在经济效益最差的细分领域。若不解决定价问题，净收入留存率将继续无故波动，关于项目支出的争论也将沦为意见之争。
大多数转型项目在诊断阶段就失败，而诊断通常是从那些将因提供解决方案而获得报酬的人那里买来的。 B2B SaaS 公司面临特定困境——增长率从 42% 跌至 32%，而 60% 的收入集中在经济效益最差的细分领域。若不解决定价问题，净收入留存率将继续无故波动，关于项目支出的争论也将沦为意见之争。
一次转型项目包含三件可分开的事：找出问题所在、决定如何应对、配备足够人手执行。咨询公司把它们捆绑出售是因为这样符合其商业模式——诊断阶段定价接近成本，通过后续交付阶段赚回利润。这不是丑闻，而是商业模式，但签约前值得了解其后果：做出诊断的人在商业上更希望诊断结果规模更大。
这类项目公布的失败率三十年来一直徘徊在 70% 左右，这本身说明问题。一个对同一件事练习几十年却仍以失败告终的领域，问题不在执行，而在更早阶段：真正的问题——哪些部分能赚回资本成本、哪些能在今年改变——尚未回答，就被转成了工作流计划。
实际检验标准是：你现在能否说出两三件出错的事，按修复顺序排列，并附上计算结果。如果能，你面对的是执行问题，购买执行能力是合理选择。如果不能，你面对的是诊断问题，在诊断完成前每花一笔执行费用，都是在更彻底地做错事。
Corporate Strategy & Transformation（目录编号 t5）提供前半部分分析：按成本和资本真实分配后，投资组合实际状况如何、哪些单元在资助哪些单元、应进行哪些改变及顺序。它不派驻人员，也不假装如此。若诚实答案是需要四十名顾问九个月，它会直接说明——这比第一张发票更省钱。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 在任何人同意问题所在之前就已使用“转型”一词
✓ 存在范围界定文件而非诊断
✓ 项目工作流按部门而非按问题命名
通常会让情况更糟的做法。 从将竞标交付补救措施的公司那里购买诊断，这通常会产生附带大规模补救方案的诊断。
It is for you if you run or finance a B2B SaaS company and the word "transformation" is being used before anyone has agreed what is broken. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家 B2B SaaS 公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is TechNova Solutions, a sample company profile used for testing rather than a customer — $45M ARR, 280 engineers.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn the 11-week implementation backlog into 50 reusable modules that lift services gross margin from 41 % to 55 % while preserving 23 % win rate.
| Investment required | $3.0-4.2 M total over 36 months |
| Expected return | Base case 3.8× cash-on-cash within 36 months |
| Revenue, year 1 | $47.8-49.2 M ARR |
| Revenue, year 2 | $51.5-54.0 M ARR |
| Revenue, year 3 | $56.0-60.0 M ARR |
| Exit criteria | Strategy abandoned if, by Month 12, template-able rule rate remains below 40 % OR if NRR of pilot cohort falls below 85 %; capital reallocated to Segment 2 analytics bolt-on. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For B2B SaaS 公司 it works through net revenue retention, CAC payback, ACV by segment and gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
对中型市场公司而言，诊断阶段通常为 £75k–£250k，历时六到十周，随后交付阶段通常是其数倍。大公司顾问日费率约 £1,500–£3,500，合伙人 £4,000–£8,000，典型团队混合两者，有效费率居中。但关键数字不是日费率，而是诊断与交付的比例，因为范围在此处确定。
不能，任何声称能做的工具都在兜售其他东西。软件无法运行项目办公室、与事业部总经理进行艰难对话，或提供四十人九个月。它能做的是生成分析，决定是否需要这些，以及指向何处——而这往往是最常被匆忙处理、出错代价最高的部分。
从将交付的一方那里单独购买诊断，并在接受交付投标前书面记录决定。一旦两三项改变被命名且计算写在纸上，交付招标就是有固定简报的采购。一旦不是，招标会自行设定简报，且总是更大。
Materially, yes. Growth has fallen from 42% to 32% while 60% of revenue sits in the segment with the worst economics — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are net revenue retention, CAC payback, ACV by segment, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on net revenue retention and CAC payback. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית